Opdivo paten expiry?

Opdivo is nivolumab, a monoclonal antibody PD-1 inhibitor by Bristol Myers Squibb. Patent expiry for nivolumab depends on the country and on multiple patent families (composition of matter for the antibody, methods of use, manufacturing, etc.). Because there are several patents and extensions, there isn’t a single global expiry date.

In broad terms:
- The key patent protections in major markets are expected to run into the late 2020s to early 2030s in many jurisdictions, but exact dates vary by patent family and by country.
- Regulatory data exclusivity for biologics also affects timing of biosimilar entry. In the U.S., the Biologics Price Competition and Innovation Act provides data exclusivity (roughly 12 years from first approval), which can delay biosimilar launches even after patent expiry. In the EU, there are typically up to 10 years of data/market protection, with variations by country.

If you’d like, tell me which country or region you care about (e.g., United States, European Union, China, India), and I’ll pull the current, jurisdiction-specific expiry dates and patent numbers with sources.